

Diabetes & Dialysis

Drug adjustments

Table 1. Recommended dose adjustments in diabetes medications at start of dialysis.

| | Haemodialysis | Peritoneal Dialysis |
|------------------------|---------------------|-----------------------|
| Insulin | Reduce by up to 25% | Increase by up to 30% |
| Metformin | Not recommended | Not recommended |
| Sulfonylurea | | |
| Linagliptin | 5 mg/od | 5 mg/od |
| Sitagliptin | 25 mg/od | 25 mg/od |
| Vildagliptin | 50 mg/od | 50 mg/od |
| Alogliptin | 6.25 mg/od | 6.25 mg/od |
| SGLT2 Inhibitors | Not recommended | Not recommended |
| GLP1 Receptor Agonists | Not recommended | Not recommended |

Kidney and dialysis, 2022

GLP1 agonists: Under investigation

- increased side effects, accumulation of doses (liraglutide)
- + improved short-term glycaemic control
- + decreased insulin requirements and glucose variability (dulaglutide)